Pitt Biotech Spinout Oncorus Works Toward Clinical Trials
At the recent annual BIO International Convention, more than 18,000 attendees converged on Boston to chart the biotech industry’s future and hold nearly 47,000 partnering meetings, a certified world record. The Innovation Institute was on hand to showcase its portfolio of life science discoveries available for licensing and to seek potential partnerships with industry, entrepreneurs and investors. Once again, the red hot field of cancer immunotherapy was front and center in a lot of the discussions. While in Boston, we took the opportunity to visit Pitt spinout, Oncorus, which is developing therapies in the emerging oncolytic virus domain of immunotherapy, to get an update on the company’s progress.